JPM22, Day 4: Vertex aims to be cystic fibrosis leader into the 2030s; Gritstone hopes for new colorectal cancer biomarker

We're into the final scheduled day of the annual J.P. Morgan Healthcare Conference.

After a slate of research collaborations defined the first days of the conference, there's still plenty of action to come as companies make their final pitches to their peers, investors and industry-watchers, and look to set the stage for the year ahead.